Location History:
- Slough, GB (2010 - 2014)
- Basel, CH (2012 - 2018)
Company Filing History:
9 out of 3,223 
6 out of 168 
2 out of 4 Years Active: 2010-2018
Certainly! Here is the article about inventor Sally Oxenford:
Title: The Innovative Works of Sally Oxenford in Pharmaceutical Compounds
Introduction:
Sally Oxenford, a talented inventor based in Basel, Switzerland, has made significant strides in the field of pharmaceutical compounds. With a notable portfolio of 9 patents, Sally Oxenford has been instrumental in developing novel compounds for inhibiting lipid kinases, particularly PI3K, to address disorders such as cancer.
Latest Patents:
Sally Oxenford's latest patents focus on pharmaceutical compounds designed to inhibit lipid kinases, including PI3K. These compounds of Formulas Ia-d have shown efficacy in diagnosing, preventing, and treating disorders mediated by lipid kinases in mammalian cells. The innovative methods disclosed underscore Sally Oxenford's commitment to advancing the field of pharmacology.
Career Highlights:
Throughout her career, Sally Oxenford has worked with renowned companies such as Genentech, Inc. and F. Hoffmann-la Roche AG. Her expertise and dedication have played a crucial role in developing cutting-edge pharmaceutical compounds, contributing to the advancement of therapeutic interventions for cancer and related conditions.
Collaborations:
Sally Oxenford has collaborated with esteemed colleagues in the industry, including Adrian Folkes and Georgette M. Castanedo. These collaborations have fostered a dynamic environment for research and innovation, leading to groundbreaking discoveries in the realm of lipid kinase inhibitors.
Conclusion:
In conclusion, Sally Oxenford's groundbreaking work in the development of pharmaceutical compounds targeting lipid kinases reflects her unwavering commitment to innovation in the field of pharmacology. Her patents stand as a testament to her dedication to advancing therapeutic solutions for complex disorders, particularly cancer. Sally Oxenford's contributions continue to inspire and shape the future of pharmacological research.